This is the data Lilly has been building toward since Foundayo launched on April 1. The obesity approval came first. The cardiovascular safety data (ACHIEVE-4, HR 0.43 all-cause mortality) came second. And now the head-to-head superiority over semaglutide in type 2 diabetes completes the picture. Eli Lilly presented data at the American Diabetes Association meeting showing Foundayo (orforglipron) reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators across multiple Phase 3 type 2 diabetes trials. Lilly confirmed it will seek FDA approval for the T2D indication. If submitted under the CNPV program—as Lilly previously indicated for late Q2—and if CNPV review mirrors the 50-day Foundayo obesity precedent, a diabetes approval could come before year-end. A diabetes label transforms Foundayo’s commercial profile. The U.S. obesity addressable market is roughly 40 million adults. Adding T2D opens an additional population of approximately 37 million Americans, many of whom are already on injectable GLP-1s or insulin and may prefer an oral option with no food or water restrictions. Separately, BioSpace reported that Lilly’s $25 billion-plus M&A across 12 deals has “captured half of pharma’s 2026 capacity.” Sanofi stopped a Phase 3 in CIDP. And Hikma is investing $267 million in Ohio manufacturing.
Top Story: Foundayo Outperforms Semaglutide in Head-to-Head T2D Trials
What Happened: Eli Lilly presented data at the 2026 ADA annual meeting showing Foundayo (orforglipron) reduced blood sugar (HbA1c) more than Novo Nordisk’s semaglutide and other comparators across multiple Phase 3 type 2 diabetes trials. Lilly confirmed it will seek FDA approval for the T2D indication.
The Complete Data Package
The ADA head-to-head data are the final piece of a comprehensive clinical evidence package that Lilly has assembled over the past three months:
Superior HbA1c reduction versus semaglutide: Foundayo outperformed the current oral GLP-1 gold standard in head-to-head Phase 3 testing. For physicians choosing between oral GLP-1 options for their T2D patients, this is the most directly relevant competitive data point. It gives prescribers a data-driven rationale to choose Foundayo over oral semaglutide (Rybelsus or oral Ozempic) as the primary oral GLP-1 in their practice.
Cardiovascular safety confirmed (ACHIEVE-4): MACE-4 HR of 0.84 (non-inferior) versus insulin glargine in T2D patients with elevated cardiovascular risk. Cardiovascular safety is a regulatory requirement for diabetes drugs following the post-Avandia FDA guidance. Foundayo cleared this bar convincingly.
Mortality signal (ACHIEVE-4): 57% lower all-cause death (HR 0.43, p=0.002) versus insulin glargine. This was a pre-planned secondary endpoint in a 6,200-patient cardiovascular outcomes trial. While not the primary endpoint, a mortality signal of this magnitude in a diabetes outcomes trial is rare and clinically significant. No oral GLP-1 has demonstrated a comparable mortality reduction.
Superior weight loss versus insulin: 8.8% body weight reduction versus 1.7% weight gain with insulin glargine in ACHIEVE-4. For T2D patients who are overweight or obese—which is the majority—a drug that lowers blood sugar, reduces cardiovascular events, and produces weight loss rather than weight gain is a compelling clinical profile.
No food or water restrictions: Unlike oral semaglutide (Rybelsus), which requires patients to take the drug on an empty stomach with no more than 4 ounces of plain water and wait at least 30 minutes before eating, Foundayo has no such restrictions. For T2D patients managing complex medication regimens and daily routines, this convenience advantage translates directly to better adherence and real-world effectiveness.
What the T2D Label Means Commercially
A diabetes label transforms Foundayo from an obesity drug to a cardiometabolic franchise. The obesity indication addresses approximately 40 million U.S. adults with clinical obesity. Adding type 2 diabetes opens an additional 37 million Americans—many of whom are already being treated with injectable GLP-1s, insulin, or oral diabetes medications and represent immediate switching candidates for an oral option with superior data.
The commercial dynamics in T2D are different from obesity in important ways. Diabetes patients typically remain on therapy for life. Insurance coverage for T2D medications is well-established across commercial and Medicare populations. The Medicare GLP-1 Bridge program launching July 1 will cover both Foundayo and Zepbound, meaning Medicare beneficiaries with T2D will have access to Foundayo at a $50 copay. The combination of head-to-head superiority over semaglutide, a mortality signal, no food restrictions, and Medicare coverage creates a prescribing narrative that could rapidly shift oral GLP-1 market share from Novo to Lilly in the T2D population.
The Filing Timeline
Lilly previously indicated the T2D filing would be submitted under the CNPV program by late Q2 2026. The ADA data presentation and filing confirmation suggest the submission is imminent or may already be underway. If CNPV review mirrors the 50-day Foundayo obesity precedent, a T2D approval could arrive by Q4 2026.
The CNPV caveat remains: the program is operating under acting FDA leadership. Whether the T2D filing receives the same expedited review that characterized the obesity filing under Commissioner Makary is uncertain. But the clinical package is as strong as any T2D filing in recent memory—head-to-head superiority over the current standard, a mortality signal, cardiovascular safety, and weight loss—which should support a favorable review regardless of the review pathway.
The T2D filing also represents a test of CNPV capacity. Revolution Medicines’ daraxonrasib CNPV filing is also imminent. If both Foundayo T2D and daraxonrasib are submitted under CNPV within weeks of each other, the program will need to demonstrate it can handle multiple high-priority reviews simultaneously. The original Foundayo obesity approval was the program’s first test. Handling two major reviews concurrently would validate CNPV as an institutional capability with durable capacity rather than a single-file-at-a-time initiative.
Our Pro brief includes the full competitive scorecard comparing Foundayo versus oral semaglutide across HbA1c, weight loss, cardiovascular safety, mortality, dosing convenience, and pricing, and models the market share implications of head-to-head superiority. [Details below.]
Lilly’s $25B+ M&A Captures Half of Pharma’s 2026 Deal Capacity
What Happened: BioSpace published an analysis reporting that Lilly’s $25 billion-plus M&A spree across 12 deals has “captured half of pharma’s 2026 capacity.”
What “Half of Capacity” Means
The BioSpace analysis examined how Lilly’s acquisitions across in vivo CAR-T (Kelonia, Orna), oncology (Ajax, CrossBridge), narcolepsy (Centessa), gene editing (Profluent, Ascidian, Engage), vaccines (Curevo, LimmaTech, Vaccine Company), and China licensing (Haisco) have absorbed a disproportionate share of the available clinical-stage acquisition targets.
The concentration is remarkable. In in vivo CAR-T, Lilly owns both Kelonia (lentiviral, myeloma) and Orna (circular RNA, autoimmune)—the two most advanced programs in the space. In gene editing, Lilly has Profluent (AI recombinases), Ascidian (RNA exon editing), and Engage (non-viral delivery)—three of the most differentiated platforms. In vaccines, Lilly acquired all three of the companies it announced on a single day in May (Curevo, LimmaTech, Vaccine Company). Competitors looking to build in any of these areas find the best assets already taken.
The BioSpace piece raises the question of whether Lilly’s pace can be sustained and whether competitors—Merck, AbbVie, Pfizer, BMS—are being outmaneuvered in the M&A market. The answer depends on whether organizational bandwidth is the constraint. Lilly has the cash (its GLP-1 franchise generates the revenue to fund the deals). But integrating 12 companies simultaneously while running the Foundayo launch, managing the Zepbound commercial franchise, advancing the retatrutide TRIUMPH program, and now filing for a T2D indication requires management bandwidth that no pharmaceutical company has been tested on at this scale.
The December 7 Investment Community Meeting will be the forum where Lilly must present a coherent integration strategy. Until then, the question remains open: is 12 deals in six months the work of a company with unmatched strategic vision, or has Lilly stretched further than any single organization can execute?
Sanofi Stops Riliprubart Phase 3 in Refractory CIDP
What Happened: Sanofi announced that the riliprubart MOBILIZE Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy refractory to standard-of-care treatment will be stopped. Sanofi shares dipped 1.6%.
Why This Matters: CIDP is a rare autoimmune condition affecting peripheral nerves, causing progressive weakness and impaired sensory function. Riliprubart is an anti-C5 complement inhibitor—the same target class as AstraZeneca’s Soliris and Ultomiris, which have proven transformative in other complement-mediated diseases like paroxysmal nocturnal hemoglobinuria and myasthenia gravis.
The MOBILIZE study specifically enrolled patients refractory to existing CIDP treatments, which is the hardest-to-treat population within an already rare disease. Stopping a Phase 3 trial signals that the drug did not demonstrate sufficient benefit to justify continuation in this population. Sanofi continues to develop riliprubart in other complement-mediated conditions, but the CIDP failure narrows the franchise’s potential and removes one of the near-term catalysts from Sanofi’s pipeline.
For the CIDP treatment landscape, the failure leaves patients with refractory disease without a new therapeutic option. Current treatments (intravenous immunoglobulin, corticosteroids, plasma exchange) are effective for many patients but leave a significant minority with inadequate responses. The complement pathway seemed like a logical therapeutic target because CIDP involves autoimmune-mediated nerve damage where complement activation contributes to myelin destruction. The MOBILIZE failure suggests that blocking complement at the C5 level may not be sufficient to overcome treatment resistance in the most refractory patients—the disease mechanisms in this population may involve pathways beyond complement that require different therapeutic approaches.
For Sanofi, which is building its immunology franchise around dupilumab (Dupixent) and expanding into complement-mediated diseases, the MOBILIZE stop is a manageable setback. The company’s broader complement program continues in other indications. But each Phase 3 failure narrows the pipeline and increases the pressure on remaining programs to deliver.
Hikma Invests $267M in Ohio Manufacturing
What Happened: Hikma Pharmaceuticals outlined plans to invest $267 million in its Ohio manufacturing plants and create 350 jobs.
Why This Matters: The investment expands domestic generic and injectable drug production capacity at a time when the industry is actively onshoring pharmaceutical manufacturing. Hikma’s expansion follows the Supreme Court’s Vascepa ruling (which cleared its generic icosapent ethyl product) and aligns with the Section 232 tariff framework incentivizing U.S.-based pharmaceutical production.
The onshoring trend has accelerated throughout 2026. Hikma’s $267 million joins Regeneron’s U.S. manufacturing commitments (part of its MFN deal), India’s collective $19.1 billion pledge, CordenPharma’s AmbioPharm acquisition for U.S. peptide supply, and multiple other investments. The Section 232 tariffs take effect July 31 for large companies and September 29 for all others, creating a clear deadline that is driving capital allocation decisions toward domestic production.
Strategic Themes
1. Foundayo’s T2D Data Package Is the Most Competitive Oral GLP-1 Filing in History
Superior HbA1c reduction versus semaglutide. A 57% mortality reduction signal. No food or water restrictions. Cardiovascular safety confirmed in a 6,200-patient outcomes trial. Weight loss instead of weight gain versus insulin. Every dimension of the data package favors Foundayo over the current oral GLP-1 standard. The T2D filing, combined with the existing obesity approval and the retatrutide maximum-efficacy data, completes Lilly’s three-tier GLP-1 strategy and positions the company to dominate oral GLP-1 prescribing in both obesity and diabetes.
2. Lilly’s M&A Concentration Is Both Its Greatest Strength and Its Greatest Risk
Capturing half of pharma’s deal capacity means Lilly has first pick of the best assets across the industry. It also means the company must integrate 12 companies across eight modalities simultaneously. The GLP-1 cash engine funds the deals. The management team must execute them. Whether 12 integrations in six months is visionary or overextended will be determined by the clinical and operational outcomes over the next two to three years.
3. The GLP-1 Market Is Splitting into Obesity and Diabetes Battlefields with Different Competitive Dynamics
In obesity, the competition is about weight-loss magnitude: Foundayo at 12%, Zepbound at 22%, retatrutide at 28%, oral Wegovy at 15%. In this market, Novo’s oral Wegovy delivers more weight loss than Foundayo, and Zepbound and retatrutide are the strongest performers. Lilly’s advantage in obesity is portfolio breadth across all severity levels, not superiority at any single tier.
In diabetes, the competition shifts fundamentally. Blood sugar control, cardiovascular outcomes, mortality reduction, and dosing convenience matter as much as weight loss. And on these metrics, Foundayo’s ADA data give Lilly clear advantages: superior HbA1c reduction versus semaglutide, a 57% mortality reduction signal, and no food or water restrictions. The T2D battlefield favors Foundayo over oral semaglutide in ways that the obesity battlefield does not.
This market split means Foundayo’s commercial opportunity is actually larger in diabetes than in obesity—not because the patient population is bigger (it is comparable) but because Foundayo’s clinical advantages are more pronounced in T2D than in weight management. The ADA data make T2D Foundayo’s strongest competitive position across the entire GLP-1 landscape.
4. Pharma Onshoring Continues at Pace with Hikma’s $267M Ohio Investment
The Section 232 framework is producing measurable domestic manufacturing commitments. Each new investment adds capacity, jobs, and supply chain resilience. Whether the pace of onshoring is fast enough to meet the July 31 tariff deadline is the practical question for the industry.
Frequently Asked Questions
What did the ADA data show?
Foundayo reduced blood sugar (HbA1c) more than Novo Nordisk’s semaglutide and other comparators across multiple Phase 3 type 2 diabetes trials. Lilly confirmed it will seek FDA approval for the T2D indication.
How does Foundayo compare to oral semaglutide?
Superior HbA1c reduction (head-to-head ADA data). No food or water restrictions (oral semaglutide requires fasting). ACHIEVE-4 showed 57% lower all-cause mortality (HR 0.43) and cardiovascular safety (MACE-4 HR 0.84). Weight loss of 8.8% versus 1.7% weight gain with insulin.
When could Foundayo be approved for T2D?
Lilly targeted a late Q2 CNPV filing. If CNPV review mirrors the 50-day obesity precedent, approval could come by Q4 2026. The filing is imminent or may already be underway.
What does a T2D label add commercially?
Approximately 37 million Americans have type 2 diabetes. Adding T2D to the existing obesity label roughly doubles Foundayo’s addressable U.S. patient population. Medicare coverage at $50 copay through the Bridge program (launching July 1) further expands access.
What is the BioSpace M&A analysis?
BioSpace reported that Lilly’s $25B+ across 12 deals has “captured half of pharma’s 2026 capacity,” absorbing a disproportionate share of available clinical-stage targets across in vivo CAR-T, gene editing, vaccines, oncology, and narcolepsy.
What happened with Sanofi?
Sanofi stopped the riliprubart MOBILIZE Phase 3 in refractory CIDP. Shares dipped 1.6%. The anti-C5 complement inhibitor did not show sufficient benefit in this treatment-resistant population. Development continues in other complement-mediated conditions.
What is the Hikma investment?
$267 million in Ohio manufacturing plants, creating 350 jobs. The investment expands generic and injectable drug production and aligns with the Section 232 tariff framework’s emphasis on domestic pharmaceutical manufacturing.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Foundayo vs. Semaglutide. We compile the full competitive scorecard across HbA1c, weight loss, cardiovascular outcomes, mortality, dosing convenience, and pricing, and model the market share shift from oral semaglutide to Foundayo in the T2D population following the head-to-head superiority data.
Lilly’s $25B Problem. We analyze why capturing half of pharma’s deal capacity is both a competitive moat and an execution risk, assess which competitors are being outmaneuvered, and evaluate whether Lilly’s organizational bandwidth can support 12 simultaneous integrations.
Oral GLP-1 Competitive Landscape Updated. We reassess the oral GLP-1 market following the ADA data, model Foundayo T2D revenue contribution under CNPV approval timing, and compare the T2D and obesity competitive dynamics across Lilly and Novo portfolios.
Plus: Sanofi riliprubart CIDP failure assessment, Hikma onshoring analysis, Revolution filing watch, BIO International preview, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
